<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Hip Knee Book &#187; Arthritis Drug</title>
	<atom:link href="http://www.hipkneebook.com/tag/arthritis-drug/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.hipkneebook.com</link>
	<description>Treating Arthritis of the Hip and Knee</description>
	<lastBuildDate>Wed, 08 Feb 2012 21:30:00 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Psoriatic Arthritis &#8211; New Drug Offers Relief</title>
		<link>http://www.hipkneebook.com/main-content/psoriatic-arthritis-new-drug-offers-relief/</link>
		<comments>http://www.hipkneebook.com/main-content/psoriatic-arthritis-new-drug-offers-relief/#comments</comments>
		<pubDate>Mon, 23 Jan 2012 19:07:16 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[5 Million]]></category>
		<category><![CDATA[Academy Of Orthopedic Surgeons]]></category>
		<category><![CDATA[American Academy Of Orthopedic Surgeons]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Arthritis Relief]]></category>
		<category><![CDATA[Autoimmune Disease]]></category>
		<category><![CDATA[Flaky Skin]]></category>
		<category><![CDATA[Jaaos]]></category>
		<category><![CDATA[Population]]></category>
		<category><![CDATA[Psa]]></category>
		<category><![CDATA[Psoriasis]]></category>
		<category><![CDATA[Psoriatic Arthritis]]></category>
		<category><![CDATA[Skin Disease]]></category>
		<category><![CDATA[Substantial Benefits]]></category>

		<guid isPermaLink="false">http://www.medicalnewstoday.com/articles/240646.php</guid>
		<description><![CDATA[Around 7.5 million Americans, which is about 2.2% of the population, suffer from psoriaris, an autoimmune disease causing red, flaky skin. A new review in the Journal of the American Academy of Orthopedic Surgeons (JAAOS) reveals that patients with psoriatic arthritis (PsA), a type of arthritis that affects nearly 48% of patients with the skin disease psoriasis, gain substantial benefits from ...]]></description>
			<content:encoded><![CDATA[Around 7.5 million Americans, which is about 2.2% of the population, suffer from psoriaris, an autoimmune disease causing red, flaky skin. A new review in the Journal of the American Academy of Orthopedic Surgeons (JAAOS) reveals that patients with psoriatic arthritis (PsA), a type of arthritis that affects nearly 48% of patients with the skin disease psoriasis, gain substantial benefits from ...]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/psoriatic-arthritis-new-drug-offers-relief/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>GSK licenses ChemoCentryx arthritis treatment to bolster drug pipeline</title>
		<link>http://www.hipkneebook.com/main-content/gsk-licenses-chemocentryx-arthritis-treatment-to-bolster-drug-pipeline/</link>
		<comments>http://www.hipkneebook.com/main-content/gsk-licenses-chemocentryx-arthritis-treatment-to-bolster-drug-pipeline/#comments</comments>
		<pubDate>Fri, 06 Jan 2012 14:36:21 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Arthritis Treatment]]></category>
		<category><![CDATA[Chemocentryx]]></category>
		<category><![CDATA[Clinical Trial Results]]></category>
		<category><![CDATA[Drug Pipeline]]></category>
		<category><![CDATA[Glaxosmithkline]]></category>
		<category><![CDATA[Gsk]]></category>
		<category><![CDATA[Investigational Drug]]></category>
		<category><![CDATA[Nyse]]></category>
		<category><![CDATA[Partner]]></category>
		<category><![CDATA[Patients With Rheumatoid Arthritis]]></category>
		<category><![CDATA[Pharmaceutical Giant]]></category>
		<category><![CDATA[Phase 2]]></category>
		<category><![CDATA[Rheumatoid Arthritis]]></category>

		<guid isPermaLink="false">http://www.medcitynews.com/2012/01/gsk-licenses-chemocentryx-arthritis-treatment-to-bolster-drug-pipeline/?utm_source=rssutm_medium=rssutm_campaign=gsk-licenses-chemocentryx-arthritis-treatment-to-bolster-drug-pipeline</guid>
		<description><![CDATA[GlaxoSmithKline (NYSE:GSK) is strengthening its drug pipeline with an experimental arthritis treatment from drug partner ChemoCentryx. The pharmaceutical giant has exercised an option for an exclusive license to develop ChemoCentryx’s investigational drug CCX354, which recently produced positive phase 2 clinical trial results in a study of patients with rheumatoid arthritis. Under terms of the ...]]></description>
			<content:encoded><![CDATA[GlaxoSmithKline (NYSE:GSK) is strengthening its drug pipeline with an experimental arthritis treatment from drug partner ChemoCentryx. The pharmaceutical giant has exercised an option for an exclusive license to develop ChemoCentryx’s investigational drug CCX354, which recently produced positive phase 2 clinical trial results in a study of patients with rheumatoid arthritis. Under terms of the ...]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/gsk-licenses-chemocentryx-arthritis-treatment-to-bolster-drug-pipeline/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA accepts application for Pfizer arthritis drug</title>
		<link>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug-3/</link>
		<comments>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug-3/#comments</comments>
		<pubDate>Wed, 21 Dec 2011 01:34:40 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Adults]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Experimental Drug]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[Food And Drug]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Rheumatoid Arthritis]]></category>

		<guid isPermaLink="false">http://www.seattlepi.com/business/article/FDA-accepts-application-for-Pfizer-arthritis-drug-2414618.php</guid>
		<description><![CDATA[FDA accepts application for Pfizer arthritis drug NEW YORK (AP) — Drugmaker Pfizer Inc. says the Food and Drug Administration has accepted its application for approval of its experimental drug for adults with moderate to severe rheumatoid arthritis.]]></description>
			<content:encoded><![CDATA[FDA accepts application for Pfizer arthritis drug NEW YORK (AP) — Drugmaker Pfizer Inc. says the Food and Drug Administration has accepted its application for approval of its experimental drug for adults with moderate to severe rheumatoid arthritis.]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug-3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA accepts application for Pfizer arthritis drug</title>
		<link>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug-2/</link>
		<comments>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug-2/#comments</comments>
		<pubDate>Tue, 20 Dec 2011 20:13:12 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Adults]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Experimental Drug]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[Food And Drug]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Rheumatoid Arthritis]]></category>

		<guid isPermaLink="false">http://www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2011/12/20/financial/f112901S01.DTL</guid>
		<description><![CDATA[(12-20) 11:29 PST NEW YORK, (AP) -- Drugmaker Pfizer Inc. says the Food and Drug Administration has accepted its application for approval of its experimental drug for adults with moderate to severe rheumatoid arthritis....]]></description>
			<content:encoded><![CDATA[(12-20) 11:29 PST NEW YORK, (AP) -- Drugmaker Pfizer Inc. says the Food and Drug Administration has accepted its application for approval of its experimental drug for adults with moderate to severe rheumatoid arthritis....]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA accepts application for Pfizer arthritis drug</title>
		<link>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug/</link>
		<comments>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug/#comments</comments>
		<pubDate>Tue, 20 Dec 2011 19:29:13 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Adults]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Experimental Drug]]></category>
		<category><![CDATA[Fda]]></category>
		<category><![CDATA[Food And Drug]]></category>
		<category><![CDATA[Food And Drug Administration]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pfizer Inc]]></category>
		<category><![CDATA[Rheumatoid Arthritis]]></category>

		<guid isPermaLink="false">http://finance.yahoo.com/news/fda-accepts-application-pfizer-arthritis-192905018.html</guid>
		<description><![CDATA[Drugmaker Pfizer Inc. says the Food and Drug Administration has accepted its application for approval of its experimental drug for adults with moderate to severe rheumatoid arthritis.The FDA says it expects ...]]></description>
			<content:encoded><![CDATA[Drugmaker Pfizer Inc. says the Food and Drug Administration has accepted its application for approval of its experimental drug for adults with moderate to severe rheumatoid arthritis.The FDA says it expects ...]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/fda-accepts-application-for-pfizer-arthritis-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Mole-rats may help identify arthritis drug</title>
		<link>http://www.hipkneebook.com/main-content/mole-rats-may-help-identify-arthritis-drug/</link>
		<comments>http://www.hipkneebook.com/main-content/mole-rats-may-help-identify-arthritis-drug/#comments</comments>
		<pubDate>Sat, 17 Dec 2011 03:48:40 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Inflammatory Arthritis]]></category>
		<category><![CDATA[Insensitivity]]></category>
		<category><![CDATA[Naked Mole Rats]]></category>
		<category><![CDATA[Scientists]]></category>
		<category><![CDATA[Upi]]></category>

		<guid isPermaLink="false">http://www.upi.com/Science_News/2011/12/16/Mole-rats-may-help-identify-arthritis-drug/UPI-95601324092681/</guid>
		<description><![CDATA[WASHINGTON, Dec. 16 (UPI) -- The insensitivity of naked mole-rats to acid-induced pain could lead to better treatments for humans suffering from inflammatory arthritis, U.S. scientists say.]]></description>
			<content:encoded><![CDATA[WASHINGTON, Dec. 16 (UPI) -- The insensitivity of naked mole-rats to acid-induced pain could lead to better treatments for humans suffering from inflammatory arthritis, U.S. scientists say.]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/mole-rats-may-help-identify-arthritis-drug/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arthritis Treatment Response Higher In Those Who Are Younger, Less Disabled</title>
		<link>http://www.hipkneebook.com/main-content/arthritis-treatment-response-higher-in-those-who-are-younger-less-disabled/</link>
		<comments>http://www.hipkneebook.com/main-content/arthritis-treatment-response-higher-in-those-who-are-younger-less-disabled/#comments</comments>
		<pubDate>Tue, 08 Nov 2011 00:35:42 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Antirheumatic Drugs]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Arthritis Treatment]]></category>
		<category><![CDATA[Disability]]></category>
		<category><![CDATA[Etanercept]]></category>
		<category><![CDATA[Measures]]></category>
		<category><![CDATA[Treatment Response]]></category>

		<guid isPermaLink="false">http://www.thirdage.com/news/arthritis-treatment-response-higher-in-those-who-are-younger-less-disabled_11-08-2011</guid>
		<description><![CDATA[The arthritis treatment drug etanercept is more effective in younger patients who have low measures of disability and less history of using disease-modifying antirheumatic drugs, a new study reports.]]></description>
			<content:encoded><![CDATA[The arthritis treatment drug etanercept is more effective in younger patients who have low measures of disability and less history of using disease-modifying antirheumatic drugs, a new study reports.]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/arthritis-treatment-response-higher-in-those-who-are-younger-less-disabled/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis Announces Potential Treatment For Juvenile Arthritis</title>
		<link>http://www.hipkneebook.com/main-content/novartis-announces-potential-treatment-for-juvenile-arthritis/</link>
		<comments>http://www.hipkneebook.com/main-content/novartis-announces-potential-treatment-for-juvenile-arthritis/#comments</comments>
		<pubDate>Fri, 16 Sep 2011 22:17:20 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Belgium]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[Generic Name]]></category>
		<category><![CDATA[Juvenile Arthritis]]></category>
		<category><![CDATA[Measuring System]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pediatric Rheumatology]]></category>
		<category><![CDATA[Placebo]]></category>
		<category><![CDATA[Swiss]]></category>
		<category><![CDATA[System Improvements]]></category>

		<guid isPermaLink="false">http://www.thirdage.com/news/novartis-announces-potential-treatment-for-juvenile-arthritis_09-16-2011</guid>
		<description><![CDATA[Swiss drug maker Novartis announced a potential treatment for a severe form of juvenile arthritis at the 2011 European Pediatric Rheumatology Congress in Belgium. The drug, which goes by the generic name canakinumab, did better than a placebo in a late-stage study measuring system improvements, the Associated Press reports. Almost 84 percent of patients who took the compound, labeled ACZ885 ...]]></description>
			<content:encoded><![CDATA[Swiss drug maker Novartis announced a potential treatment for a severe form of juvenile arthritis at the 2011 European Pediatric Rheumatology Congress in Belgium. The drug, which goes by the generic name canakinumab, did better than a placebo in a late-stage study measuring system improvements, the Associated Press reports. Almost 84 percent of patients who took the compound, labeled ACZ885 ...]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/novartis-announces-potential-treatment-for-juvenile-arthritis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis announces arthritis drug study results</title>
		<link>http://www.hipkneebook.com/main-content/novartis-announces-arthritis-drug-study-results-2/</link>
		<comments>http://www.hipkneebook.com/main-content/novartis-announces-arthritis-drug-study-results-2/#comments</comments>
		<pubDate>Fri, 16 Sep 2011 19:00:38 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Improvements]]></category>
		<category><![CDATA[Juvenile Arthritis]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Novartis Ag]]></category>
		<category><![CDATA[Placebo]]></category>
		<category><![CDATA[Swiss]]></category>

		<guid isPermaLink="false">http://news.yahoo.com/novartis-announces-arthritis-drug-study-results-190038304.html</guid>
		<description><![CDATA[Swiss drugmaker Novartis AG said Friday a potential treatment for a severe form of juvenile arthritis did better than a placebo in a late-stage study measuring symptom improvements.]]></description>
			<content:encoded><![CDATA[Swiss drugmaker Novartis AG said Friday a potential treatment for a severe form of juvenile arthritis did better than a placebo in a late-stage study measuring symptom improvements.]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/novartis-announces-arthritis-drug-study-results-2/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Novartis announces arthritis drug study results</title>
		<link>http://www.hipkneebook.com/main-content/novartis-announces-arthritis-drug-study-results/</link>
		<comments>http://www.hipkneebook.com/main-content/novartis-announces-arthritis-drug-study-results/#comments</comments>
		<pubDate>Fri, 16 Sep 2011 19:00:16 +0000</pubDate>
		<dc:creator>Content Keyword RSS</dc:creator>
				<category><![CDATA[Main Content]]></category>
		<category><![CDATA[Arthritis]]></category>
		<category><![CDATA[Arthritis Drug]]></category>
		<category><![CDATA[Improvements]]></category>
		<category><![CDATA[Juvenile Arthritis]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Novartis Ag]]></category>
		<category><![CDATA[Placebo]]></category>
		<category><![CDATA[Swiss]]></category>

		<guid isPermaLink="false">http://biz.yahoo.com/ap/110916/us_novartis_drug_trial.html?.v=1</guid>
		<description><![CDATA[Swiss drugmaker Novartis AG said Friday a potential treatment for a severe form of juvenile arthritis did better than a placebo in a late-stage study measuring symptom improvements.]]></description>
			<content:encoded><![CDATA[Swiss drugmaker Novartis AG said Friday a potential treatment for a severe form of juvenile arthritis did better than a placebo in a late-stage study measuring symptom improvements.]]></content:encoded>
			<wfw:commentRss>http://www.hipkneebook.com/main-content/novartis-announces-arthritis-drug-study-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

